1. Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase
- Author
-
Sébastien L. Degorce, Steven C. Glossop, Alan Lau, Elaine Cadogan, Barlaam Bernard Christophe, Richard Ducray, Kurt Gordon Pike, Andrew G. Thomason, Gilles Ouvry, Allan Dishington, Franck Lach, Lorraine A. Hassall, Thomas M. McGuire, and Thorsten Nowak
- Subjects
0301 basic medicine ,Stereochemistry ,Administration, Oral ,Mice, Nude ,Antineoplastic Agents ,Ataxia Telangiectasia Mutated Proteins ,Pharmacology ,Mice ,Structure-Activity Relationship ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,In vivo ,Drug Discovery ,Animals ,Humans ,Structure–activity relationship ,Transferase ,Protein Kinase Inhibitors ,Cell Proliferation ,ADME ,Dose-Response Relationship, Drug ,Molecular Structure ,Kinase ,Drug discovery ,Quinoline ,Neoplasms, Experimental ,Xenograft Model Antitumor Assays ,030104 developmental biology ,chemistry ,030220 oncology & carcinogenesis ,Quinolines ,Molecular Medicine - Abstract
A novel series of 3-quinoline carboxamides has been discovered and optimized as selective inhibitors of the ataxia telangiectasia mutated (ATM) kinase. From a modestly potent HTS hit (4), we identified molecules such as 6-[6-(methoxymethyl)-3-pyridinyl]-4-{[(1R)-1-(tetrahydro-2H-pyran-4-yl)ethyl]amino}-3-quinolinecarboxamide (72) and 7-fluoro-6-[6-(methoxymethyl)pyridin-3-yl]-4-{[(1S)-1-(1-methyl-1H-pyrazol-3-yl)ethyl]amino}quinoline-3-carboxamide (74) as potent and highly selective ATM inhibitors with overall ADME properties suitable for oral administration. 72 and 74 constitute excellent oral tools to probe ATM inhibition in vivo. Efficacy in combination with the DSB-inducing agent irinotecan was observed in a disease relevant model.
- Published
- 2016